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A B S T R A C T
Toxicity of ZnO nanoparticles (NPs) are often related to the release of Zn2+ ions due to their dissolution. Studies
also suggest that the toxicity of ZnO NPs cannot be solely explained by the release of Zn2+ ions; however, there is
a lack of direct evidence of ZnO particulate eﬀects. This study compared the acute toxicity of ZnO NPs and ZnSO4
following intranasal exposure using a combination of metallomics and metabolomics approaches. Signiﬁcant
accumulation of Zn in the liver was only found in the ZnO NP treatment, with 29% of the newly accumulated Zn
in the form of ZnO as revealed by X-ray ﬁne structure spectroscopy (XAFS). This is the ﬁrst direct evidence
suggesting the persistence of ZnO NPs in liver upon intranasal exposure. Although both ZnO NPs and ZnSO4
altered the metabolite proﬁles, with some overlaps and considerable speciﬁcity, of both liver and plasma
samples, more and distinct metabolites in the liver and opposite eﬀects in the plasma were altered by ZnO NPs
compared with ZnSO4, consistent with no accumulation of Zn detected in liver from ZnSO4. Speciﬁcally, a large
number of antioxidant-related compounds and energetic substrates were exclusively elevated in the liver of ZnO
NP-treated animals. These ﬁndings provided direct evidence that persistence of ZnO NPs induced particle-spe-
ciﬁc eﬀects on the antioxidant systems and energy metabolism pathways.
1. Introduction
Zinc oxide nanoparticles (ZnO NPs) have been incorporated into
many consumer products due to their unique photocatalytic, electronic,
optical, dermatological and antibacterial properties (Siddiqi et al.,
2018). With their increasing production and use, human exposure to
ZnO NPs is inevitable. Although most of the manufacturing processing
takes places in closed systems, the postproduction and packaging pro-
cesses would inevitably increase their risk of being released into the
ambient air, where aerosol forms, causing unintentional inhalation
exposure for workers and the public (Osmond and Mccall, 2010).
Welding fumes are also a source of ZnO NP aerosol exposure (Fine et al.,
2000). Therefore, the health risk of ZnO NPs must be fully understood
to allow appropriate regulation.
The adverse eﬀects of ZnO NPs are often related to the dissolution of
ZnO NPs due to the fact that ZnO tends to dissolve in biological en-
vironment. Xia et al. found that ZnO NPs induced cytotoxicity in both
human and murine cell cultures, and that ZnO dissolution may con-
tribute to the toxicity of ZnO NPs (Xia et al., 2008). Consistent with this
ﬁnding, intracellular release of ionic Zn was believed to attribute to the
cytotoxicity of ZnO nanowires to human monocyte macrophages
(Müller et al., 2010). In vivo studies also suggest the main contribution
of dissolved Zn2+ ions to the toxicity of ZnO NPs, shown by the evi-
dence that lung instillation of Zn2+ ions induced similar pathologies as
were elicited by ZnO NPs (Cho et al., 2011). Studies suggested that the
toxicity of ZnO NPs cannot be fully explained by the release of Zn2+
ions (Hua et al., 2014). For example, ZnO NP toxicity was also highly
dependent on the particle size (Khare et al., 2015). The mechanism of
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ZnO NP action and the relative contribution of the particulate and ionic
form to the ZnO NP toxicity is still not clear.
Recent studies have shown that omics approaches are increasingly
powerful tools in the ﬁeld of nanotoxicology (Fröhlich, 2017). Meta-
bolomics has been used as a powerful tool for deciphering organismal
response to stimuli, allowing detection of subtle metabolic alteration
(Nicholson and Lindon, 2008). It is a non-hypothesis driven method
that can acquire insights into the mechanism of NP induced biological
eﬀects.
In this study, a combination of metabolomics and metallomics ap-
proaches were applied. We exposed the rats to ZnO NPs as well as
ZnSO4 intranasally to simulate exposure through the respiratory tract.
We then used metabolomics aiming to gain mechanistic insights into
the action of ZnO NPs and ZnSO4. Since later analysis of tissue dis-
tribution of Zn upon exposure to ZnO NPs showed that liver rather than
lung was a main accumulator of Zn, and given the fact that liver is
usually the most important target organ of nanomaterials (Chen et al.,
2007), a signiﬁcant metabolic response in liver to the accumulated Zn
might be expected. Therefore, we analyzed the metabolic proﬁle in
liver. Plasma sample was also analyzed. Synchrotron radiation - based
X-ray ﬁne structure spectroscopy (XAFS) was used to analyze the che-
mical speciation of Zn in liver, which allowed to identify any particu-
late or transformed Zn in the tissue. Our results showed presence of
particulate form of ZnO and transformed form of Zn (Zn-histidine
complex) in liver and clear evidence of particle-speciﬁc eﬀects of ZnO
NPs.
2. Materials and methods
2.1. Materials
Spherical ZnO NPs (31 ± 5 nm) were procured from Hang Zhou
Wan Jing New Material Co., Ltd. (Hangzhou, China). Morphology and
size of ZnO NPs were measured on a TEM (JEOL 2100, USA) (Figure
S1a). Hydrodynamic size and zeta potential were measured using a
Zetasizer Nanodevice (Malvern, Panalytical, UK) (Figure S1b and S1c).
ZnSO4 was purchased from Sigma-Aldrich. Ultraperformance liquid
chromatography grade acetonitrile (Merck, Germany), methanol
(Merck, Germany), ammonium acetate (Sigma-Aldrich, Germany), and
ultrapure water (18.2 MΩ-cm, Millipore, Billerica, MA) were used for
solvent preparation in the metabolomics analysis. Assay kits for as-
partate aminotransferase (AST) (catalogue no. C010-2), alanine ami-
notransferase (ALT) (catalogue no. C009-2), alkaline phosphatase (ALP)
(catalogue no. A059-2), superoxide dismutase (SOD) (catalogue no.
A001-3), glutathione (GSH) (catalogue no. A006-2), malondialdehyde
(MDA) (catalogue no. A003-1), and ROS kit (catalogue no. E004-1-1)
were purchased from Nanjing Jiancheng Bioengineering Institute
(Nanjing, China). A kit for catalase (CAT) (catalogue no. S0051) was
purchased from Beyotime (Shanghai, China). A Rat Inﬂammatory Cy-
tokines Multi-Analyte ELISArrayTM Kit was purchased from Qiagen
(Hilden, Germany).
2.2. Animal exposure and sample collection
Animal procedures were conducted following the Chinese Academy
of Science Animal Care guidelines and approved by the Research Center
for Eco-Environmental Sciences Animal Care Committee. Four-week-
old male Sprague-Dawley rats (~av. 130 g, Charles River Laboratories,
China) were housed in pairs in cages with a 12-h light/dark cycle (8AM
lights on) with food and water ad libitum. After one week’s acclimati-
zation, rats (av. 170 g) were randomly divided into three groups of
thirty and intranasally administered with one single dose of ZnO NPs or
ZnSO4 and exposed for 7 days. A selection of 7 days of exposure not
only allow for examining the acute toxicity, but also for monitoring the
dissolution of ZnO NPs. We utilized equimolar Zn concentrations of
ZnSO4 to simulate a scenario whereby the ZnO NPs completely dissolve
following uptake into the organism. The hypothesis being tested was
that rapid dissolution of the ZnO NPs following uptake would lead to
equivalent system perturbations as those induced by direct exposure to
Zn ions, and that any diﬀerential expression between the two condi-
tions would be the result of NPs inducing a particle-speciﬁc eﬀect.
The doses used in the present study were chosen referring to a
previous study which used a dose of 1.6 mg Zn (in the form of ZnO NPs)
per rat for intranasal exposure (Gao et al. 2013). In the present study, a
lower (0.85 mg per rat), nearly equivalent (1.7 mg per rat) and higher
(2.56 mg per rat) dose than that used in this previous study were
adopted for pre-experiment. Preliminary analyses of the tissue dis-
tribution of Zn showed that dose of 0.85 and 1.7 mg per rat of ZnO NP
exposure did not induce signiﬁcant accumulation of Zn in liver as well
as other organs (Table S1 and Figure S2). In order to be able to detect
and analzye the chemical speciation of the newly accumulated Zn by
XAFS, which was a core goal of the present study in order to correlate
speciation with biological eﬀect, dose of 2.56 mg per rat was used for
further experiments.
ZnO NPs and ZnSO4 were dissolved in 0.1% sodium carboxymethyl
cellulose solution (SCMC) to achieve equal Zn elemental concentrations
of 64 mg/mL. For exposure, animals were lightly anesthetized by in-
haled isoﬂurane and a total of 40 μL of 0.1% SCMC (control, CT), ZnO
NPs, or ZnSO4 were administered intranasally to rats, 10 μL at a time,
alternating between each naris every 2 min. This provided a total do-
sage of 2.56 mg of Zn element per animal in both treatments. Animals
were left undisturbed until 7 days post exposure, when they were sa-
criﬁced and blood and organs collected. Brieﬂy, each rat was weighed,
and then anaesthetized in an isoﬂurane - ﬁlled chamber. Immediately
after anesthesia, the whole blood was withdrawn by directly puncturing
the aorta using a syringe and then transferred to heparin or EDTA-
coated tubes or nonanticoagulated tubes (2 mL per tube). Heparin or
EDTA-anticoagulated whole blood was centrifuged at 2000g for 10 min
at 4℃, and the supernatant (plasma) was taken and immediately frozen
in liquid nitrogen and then stored at−80℃ before further analysis, e.g.
either metabolomic (Heparin) or proinﬂammatory cytokines and en-
zyme assay kit analyses (EDTA). Some of the whole blood samples with
EDTA as anticoagulant were immediately analyzed for hematological
parameter determination. Serum samples were obtained by centrifu-
ging the whole blood without any anticoagulant at 3000g for 10 min at
4 ℃, and blood biochemical analyses were performed immediately.
Organ samples were dissected, weighed, and washed 3 times with
1 × PBS, and then analyzed or snap - frozen in liquid nitrogen and
stored at−80 °C for futher study. All frozen samples were ground prior
to extraction of metabolites.
2.3. Zn contents in whole blood and organs
All organ samples were lyophilized at −80 °C for 96 h in a freeze
dryer (Songyuan Huaxing Corp., Beijing, China) and weighed. Samples
were then ground into powder and digested using mixtures of nitric
acids (HNO3) and hydrogen peroxide (H2O2) with a volume ratio of 3:1
on a MARS 6 microwave digestion system (CEM, UK). For blood, 2 mL
samples were used for digestion. Samples were analyzed on a Perkin
Elmer Optima 8000 inductively coupled plasma mass spectrometry
(ICP-OES) (Perkin Elmer, Shelton, CT, U.S.A) in radial mode using
wavelength of 206.2 nm, with a plasma ﬂow rate of 8 L/min, auxiliary
ﬂow rate of 0.2 L/min and nebulizer ﬂow of 0.7 L/min. Each sample
was pumped into the ICP-OES at 1 mL/min with a 30 s ﬂush between
samples to eliminate carryover. A calibration curve was generated be-
tween 0.01 and 5 mg/L with an R2 of 0.999994, the limit of detection
determined by Zn standard addition was 1.2 μg/L with an limit of
quantitation of 3.5 μg/L. All samples were analyzed in triplicate and
each of these included analytical triplicates, the mean relative standard
deviation (RSD) for replicates was 5.7% with a median of 5.6%.
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2.4. Zn chemical species analysis by XAFS
To analyze the Zn chemical speciation, dry liver and spleen tissues
were ground to ﬁne powders, and pressed into thin slices (~2 mm) for
analysis. XAFS spectra of the samples were collected on beamline 1W1B
at the Beijing Synchrotron Radiation Facility (BSRF). The storage ring
was run at 2.5 GeV with current intensity of 50 mA during the spectra
collection. Zn K-edge (5723 eV) spectra were collected at ambient
temperature in ﬂuorescence mode. XAFS spectra of ZnSO4, ZnO NPs, Zn
acetate, Zn3(PO4)2, Zn-Cystine, Zn citrate, and Zn - Histidine were
collected as standard references. LCF analyses of the XANES spectra
were performed using the software program ATHENA to identify and
quantify Zn species in tissues.
2.5. Haematological and biochemical parameters
Blood samples with EDTA as anticoagulant were analyzed using the
hematology analyzer DxH 520 (Beckman Coulter Inc., USA) to quantify
hematological parameters. Blood chemical parameters were determined
in serum samples using a Hitachi7100 automated biochemical analyzer
(Hitachi Co., Japan).
Release of inﬂammatory cytokines in plasma was evaluated with
Rat Inﬂammatory Cytokines Multi-Analyte ELISArrayTM Kit (Qiagen,
Hilden, Germany). Oxidative stress in liver and plasma were evaluated
by measuring the superoxide dismutase (SOD) and catalase (CAT) ac-
tivities as well as glutathione (GSH) and malondialdehyde (MDA) levels
(Nanjing Jiancheng Ltd, China). Protein contents were analyzed using
Bradford protein assay (Tiangen Biotech, Beijing, China) for normal-
ization in each enzymatic activity test. Total contents of reactive
oxygen species (ROS) were measured by a DCFH-DA (2′,7′-
Dichlorodihydroﬂuorescein diacetate) staining method (Nanjing
Jiancheng Ltd, China). All the analyses were performed according to
the manufacturer’s instructions.
2.6. Dissolution of ZnO NPs in simulated biological ﬂuids
Dissolution of ZnO NPs in ddH2O, 0.1% SCMC, artiﬁcial lysosomal
ﬂuid (ALF, pH 4.5) (Stebounova et al., 2011), rat serum, and liver S9
extract was analyzed by measuring the Zn2+ released into the solution.
Brieﬂy, ZnO NP suspensions (100 mg/L) in 25 mL ddH2O, 0.1% SCMC
and ALF media were prepared and incubated for 24 and 48 h at 37 °C.
For serum and liver S9 extract, ZnO NPs suspension were prepared in
rat serum and diluted S9 extract (0.1 mg/mL) and incubated at 37 °C for
7 days. Samples were taken at diﬀerent time points and centrifuged at
11,000g for 15 min. The supernatants were collected and diluted with
2% nitric acids for ICP-OES analysis (PerkinElmer, USA). A range of Zn
standard solutions (0.1, 1, 5, 10, 50, 100, 500 μg/L) were used for
calibration. The recovery rates of Zn was tested to be 99.7%.
2.7. Metabolite proﬁling of plasma and liver samples
Untargeted metabolomics was applied to plasma and liver samples
which were analyzed by liquid chromatography-tandem MS (LC-MS/
MS). For quantitative analysis of metabolites, hydrophilic interaction
liquid chromatography (HILIC) triple quadrupole (QqQ) tandem mass
spectrometry (MS/MS) was utilized. Details of the sample preparation,
instrumentation and data analysis are described as follows.
2.7.1. Sample preparation for metabolomics analysis
The plasma samples were thawed on ice, and thoroughly vortexed.
For each sample, 100 μL was taken and transferred into a 1.5 mL
Eppendorf tube. Then 400 μL of cold methanol / acetonitrile (1:1, v/v)
was added to each sample. The samples were mixed by vigorous vor-
texing and kept at−20 °C for 1 h. Then the samples were centrifuged at
14,000g for 20 min at 4 °C. A 300 μL aliquot of supernatant was
transferred into a glass sampling vial and vacuum – dried at room
temperature. Then 100 μL of acetonitrile / water (1:1, v/v) was added.
The samples were vortexed vigorously, and centrifuged at 14,000g for
15 min at 4 °C. The resultant supernatants were stored at−80 °C before
metabolomics analysis. The quality control (QC) samples were prepared
by mixing equal volumes of aliquots of each plasma sample (30 sam-
ples) with all other steps as described above.
Liver samples were ﬁnely ground into powder in liquid nitrogen. For
each sample, 60 mg was transferred to a 1.5 mL Eppendorf tube and
mixed with 1 mL methanol/acetonitrile/H2O (2:2:1, v/v/v) by vor-
texing vigorously. Samples were ultrasonicated for 30 min at 4 °C twice,
and then kept at −20 °C for 1 h for protein precipitation. The pre-
cipitates were removed by centrifugation at 13,000 rpm at 4 °C for
15 min. The supernatants were collected, lyophilized, and stored at
−80 °C prior to metabolomics analysis. QC samples were prepared by
mixing equal volumes of each liver sample, with all other steps as de-
scribed above.
2.7.2. Ultraperformance liquid chromatography quadrupole time-of-ﬂight
tandem mass spectrometry (UHPLC-QTOF-MS/MS) for untargeted
metabolomics
The supernatants prepared above were transferred to the auto-
sampler injection vial in an Agilent 1290 Inﬁnity liquid chromato-
graphy system coupled to a Triple TOF 5600 System (AB SCIEX,
Concord, ON). The prepared sample solution was injected into an
ACQUITY UPLC BEH Amide column (1.7 μm, 2.1 mm × 100 mm
column, WATERS). Column temperature was maintained at 25 °C, and
ﬂow rate was 300 μL/min. The mobile phase consisted of
H2O + 25 mM ammonium acetate + 25 mM ammonium hydroxide
(mobile phase A) and acetonitrile (mobile phase B). The elution gra-
dient was as follows: 95% B from 0 to 1 min; 95% − 65% B from 1 to
14 min; 65%−40% B from 14 to 16 min; B was held at 40% from 16 to
18 min; 40%- 95% B from 18 to 18.1 min; B was held at 95% from 18.1
to 23 min for equilibration. The sample tray temperature was kept at
4 °C throughout the analyses. Samples were analyzed in random order,
and QC samples were injected at regular intervals (every 10 samples)
throughout the analytical run to monitor the stability and repeatability
of the UPLC-QTOF system. Detection was performed through electro-
spray ionization (ESI) positive and negative modes.
2.7.3. HILIC-QqQ-MS for targeted metabolomics
Sample preparation was carried out as described above. The sam-
ples were analyzed using a Waters I-class liquid chromatography system
with ACQUITY UPLC BEH Amide column (1.7 μm, 2.1 mm × 100 mm
column, WATERS) coupled to a 5500 QqQ MS (SCIEX). Column tem-
perature was maintained at 40 °C, and ﬂow rate was 300 μL/min. The
QC samples were injected at regular intervals (every 6 samples)
throughout the analytical run. Detection was performed through ESI
positive and negative modes. The MS parameters were as follows: ca-
pillary voltage of 4000 V in positive ion mode or −3500 V in negative
mode.
2.7.4. Metabolomics data analysis
The original UHPLC-QTOF-MS data were converted to .mzXML
format using ProteoWizard, and then exported to XCMS software for
peak alignment, retention time adjustment, and extraction of peak in-
tensities. The peak area normalized data was imported into SIMCA-P
14.1 software (Umetrics, Umea, Sweden), and pareto-scaled before
multivariate statistical analysis and univariate analysis. The original
QqQ-MS data were analyzed using MRMAnalyzer as described by Cai
et al. (2015).
Unsupervised principal component analysis (PCA) was ﬁrst per-
formed to visualize the general separation of diﬀerent groups. Then, a
supervised clustering method, partial least - squares discriminant ana-
lysis (PLS-DA), was used to classify the samples and ﬁnd the relevant
variables related to the sample groupings. The model was validated
using a 7-fold cross validation method and tested with 200 random
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permutations to assess the predictive variation of the model. The re-
sultant parameters, the R2Y and Q2 values, were indicators of the
quality of the model.
Variable importance in projections (VIP) scores indicate the im-
portance of a variable to the entire model. VIP scores obtained from the
PLS-DA model were used to assess the contribution a variable makes to
the model. Metabolites that had VIP > 1 are regarded as responsible
for separation and deﬁned as discriminating metabolites. Based on the
multivariate analysis and original MS spectra, the discriminating me-
tabolites were identiﬁed by comparison with the human metabolome
database (http://www.hmdb.ca). The metabolite levels in the treated
groups were compared with those in the vehicle control group using
Student’s t test statistical analysis. Metabolites that had VIP > 1 and
p < 0.05 are deﬁned as signiﬁcantly changed metabolites.
MetaboAnalyst (https://www.metaboanalyst.ca/) was used for the
functional enrichment analysis of the disturbed metabolites (Xia et al.,
2009).
2.8. Statistical analysis
Data are expressed as mean ± SD and were analyzed with
GraphPad InStat software (Version 3, GraphPad Software, Inc., La Jolla,
CA). Student’s t-test was applied for comparison between control and
ZnO NPs or ZnSO4 treatment group. Diﬀerences were considered as
statistically signiﬁcant at values of *p < 0.05, ** p < 0.01, and ***
p < 0.001.
3. Results
3.1. Accumulation and speciation of Zn in blood and targeted organs
Intranasal exposure of rats to ZnO NPs resulted in signiﬁcant ac-
cumulation of Zn in liver, kidney, spleen, and testis (Fig. 1a–d) but not
in blood and other organs (Figure S3) at 7 days post-exposure. Newly
accumulated Zn in those tissues accounted for 23.5% (8.5 mg/kg),
14.6% (4.6 mg/kg), 29.2% (9.2 mg/kg) and 10.2% (6.6 mg/kg) of total
Zn detected in the corresponding tissue, respectively. However, there
was no signiﬁcant accumulation of Zn in those tissues and blood after
ZnSO4 treatment (Fig. 1a–d). Diﬀerent from our results, Konduru et al.
(2014) showed that bone, bone marrow, skin and skeletal muscle ac-
cumulated much higher fraction of Zn than liver, spleen, kidney and
testis 7 days after intratracheal instillation of ZnO or SiO2-coated ZnO,
suggesting that exposure pathway greatly impact the pharmacokinetics
and tissue distribution of ZnO NPs (Konduru et al., 2014).
We then analyzed the XAFS K-edge spectra of Zn in liver and spleen
samples where signiﬁcant Zn was accumulated. The results showed si-
milar features between control and ZnO NPs or ZnSO4 treatment in both
samples (Fig. 1e–h), indicating that Zn predominantly presented as the
ionic form as per that found in normal liver and spleen. We further
preformed linear combination ﬁtting (LCF) analysis using diﬀerent Zn
compounds as the reference (Figure S4), particularly, we also used the
spectra of liver or spleen samples from control group as a reference. In
the liver of rat treated with ZnO NPs, 89.8% of the Zn resembled that in
control group and 3.4% was in the form of Zn-His complex, with the
remaining 6.8% in the form of ZnO (Fig. 1i). Since the total Zn in the
liver included the background (76.5%) and newly accumulated Zn
(23.5%), we did a calculation and found that 29% of the accumulated
Zn presented as ZnO. In the liver of ZnSO4 group, 97.7% of the Zn
resembled that in control group, with the rest in the form of Zn-His and
Zn-Cys complexes (Fig. 1j). In the spleen of ZnO group, 97% of the Zn
resembled that in control group; only 0.7% of the Zn (2.3% of the newly
accumulated Zn) was found as ZnO, with the remaining in the forms of
Zn-His (1.3%) and Zn-Cys (1%) (Fig. 1k). In ZnSO4 group, 96.8% of the
Zn resembled that in control group, with the remaining presented as Zn-
His (2.7%) and Zn-Cys (0.5%) (Fig. 1l).
3.2. Animal weights and blood chemical and hematological examination
No signiﬁcant diﬀerences in body weights were observed between
treated and control animals (Table S2). Heart and lung weights were
decreased following ZnSO4 exposure, while thymus weights increased
signiﬁcantly (p < 0.05) after ZnO NP exposure. The relative brain
weights decreased signiﬁcantly (p < 0.01) in the ZnSO4 group. The
relative heart weights decreased in rats exposed to both treatments
(Table S2).
Blood parameters were slightly aﬀected in the ZnSO4 exposed group
(Table S3), with a signiﬁcant decrease of amylase (p < 0.05) and a
signiﬁcant increase of glucose levels (p < 0.05). The biochemical
markers for liver function including globulin, albumin, albumin/glo-
bulin ratio, bile acid and bilirubin, and those indicators of other organ
diseases, including creatinine, uric acid, creatine phosphokinase, lac-
tate dehydrogenase, total protein, calcium, phosphorus, cholesterol and
triglyceride, did not change signiﬁcantly (p > 0.05) in either treat-
ment group. Hematological parameters also did not change (Table S4).
3.3. Liver function, pro-inﬂammatory cytokines release and oxidative stress
Liver function was tested by examining the representative enzy-
matic activities. ZnSO4 treatment enhanced the alkaline phosphatase
(ALP) activity in both plasma and liver, while alanine aminotransferase
(ALT) and aspartate aminotransferase (AST) activities showed no sig-
niﬁcant change in either treatment (Fig. 2).
Signiﬁcant increases in the levels of proinﬂammatory cytokines (IL-
1β, IL-10 and TNFα) in blood plasma in both treatments were found
(Fig. 3a). ZnSO4 treatment enhanced the IL-6 level, while ZnO NP en-
hanced the release of IL-1α. No signiﬁcant release of other cytokines
was detected in either treatment (Figure S5).
Glutathione (GSH) levels in plasma were signiﬁcantly decreased by
ZnSO4 treatments (Fig. 3b). Catalase (CAT) and superoxide dismutase
(SOD) activities and MDA contents were enhanced by ZnO NP and
ZnSO4 exposure, while no excessive accumulation of ROS was found in
plasma. In liver, GSH levels were not altered, while the activity of SOD
and CAT were elevated by both treatments, and excessive amount of
MDA and ROS were produced after both ZnO NPs and ZnSO4 treatments
(Fig. 3c).
3.4. Metabolic response of plasma and liver to ZnO NPs and ZnSO4
The overall metabolic perturbations in rat blood plasma and liver
induced by ZnO NP or ZnSO4 treatment were proﬁled using non-tar-
geted metabolomics. PCA analysis (Figure S6) and supervised PLS-DA
analysis (Figure S7) of the MS data from plasma and liver showed a
clear separation between groups. In total, 55 metabolites in plasma
were altered by ZnO NP exposure, of which 33 were upregulated and 22
were downregulated; 56 metabolites were altered by ZnSO4 exposure,
with 6 upregulated and 50 downregulated (Fig. 4a), which is distinct
from that in ZnO NP group. Details of those metabolites were shown in
Figure S8a. An overlap of 21 diﬀerential metabolites was observed in
response to ZnO NPs and ZnSO4, and 17 of these overlapping meta-
bolites exhibited the same directionality with regard to their fold
change in response to ZnO NP or ZnSO4 treatment. Thirty-four meta-
bolites were altered in response to ZnO NPs only (Fig. 4a).
In liver, ZnO NPs induced alteration of more (75) metabolites than
ZnSO4 (37) (Fig. 4b), respectively. Of the 75 metabolites in the ZnO NP
group, 73 were upregulated and 2 were downregulated. In the ZnSO4
group, there were 35 upregulated and 2 downregulated metabolites
(Figure S8b). Only 13 metabolites overlapped between ZnO NP and
ZnSO4 groups; the rest 62 changed speciﬁcally in ZnO NP group
(Fig. 4b).
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3.5. ZnO NP-speciﬁc response
Signiﬁcantly perturbed metabolites in plasma and liver samples
were classiﬁed into diﬀerent groups based on their metabolic functions
and pathways (Table S5a-c and Table S6a-c). The perturbed metabolites
were involved in diverse biological pathways in both ZnO NPs and
ZnSO4 groups, although the discriminating metabolites were diﬀerent.
Fig. 4c and d show the number of perturbed metabolites involved in the
diﬀerent biological functions. In plasma, a larger number of anti-
oxidant-related metabolites were disturbed by the ZnO NP treatment
than by the ZnSO4 treatment. In the liver, more diﬀerences between
ZnO NP and ZnSO4 treatment were found, with ZnO NPs upregulating a
much higher number of metabolites that were involved in nucleotide,
lipid, amino acid, and antioxidant metabolism compared to the ZnSO4
treatment, consistent with no accumulation of Zn from ZnSO4 in the
liver.
62% and 83% of the perturbed metabolites in plasma and liver in
ZnO NP group, respectively, were ZnO NP-speciﬁc. Functional enrich-
ment analysis showed that the disturbed metabolites in plasma mainly
participate in linolenic acid metabolism, methionine, glutathione, and
betaine metabolism (Fig. 5a). In liver, ZnO NP-speciﬁc metabolites
were signiﬁcantly enriched in glutathione, glutamate, and alanine
metabolism, and biological pathways involved in carbohydrate, nu-
cleotide and lipid metabolism (Fig. 5b).
There were also some overlapping metabolites (21 in plasma and 13
in liver) that were perturbed by both ZnO NPs and ZnSO4. In plasma,
among the 17 of the overlapping metabolites that exhibited the same
directionality (Figure S8a), 3 metabolites (mannose, cystine, and gly-
ceric acid) were upregulated, while the other 14 that were involved in
glycolysis, TCA cycle, galactose, pyrimidine, tryptophan and galactose
metabolism were downregulated. In liver (Figure S8b), there were only
13 overlapping metabolites which were mainly involved in fatty acid,
glycerolipid, glucose, purine, cysteine, and glycine metabolism.
ZnSO4 also induced speciﬁc metabolic changes that were distinct
from those in ZnO NPs groups. In plasma, ZnSO4 downregulated 35
metabolites while ZnO NPs upregulated most of the perturbed meta-
bolites (34). In liver, both ZnSO4 and ZnO NPs treatments upregulated
Fig. 1. Zn contents (mg/ kg dry weight) in diﬀerent organs (a–d; n = 10) after intranasal exposure and XAFS spectra of liver (Figure e, f) and spleen (Figure g, h)
samples from ZnO NP or ZnSO4 - treated animals. Fractions of chemical species of Zn were obtained by LCF analysis (i–l). CT indicates control group without Zn
treatment. *p < 0.05 and ** p < 0.01 indicate signiﬁcant diﬀerence compared with CT. Control in XAFS spectra indicates the spectra collected from the control
group that was not treated with Zn; Zn – His and Zn – Cys indicate Zn – histidine and Zn – cysteine complexes; original line indicates the originally collected XAFS
spectra; ﬁt indicates the ﬁtting spectra using LCF analysis.
Fig. 2. Eﬀects of ZnO NPs and ZnSO4 on functional enzyme activities including
ALP, ALT and AST in plasma and liver after intranasal exposure. n = 10.
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the abundance of nearly all the altered metabolites; however, ZnSO4-
specifc metabolites (24) was much less than that by ZnO NP treatment
(62). The mostly enriched pathway for ZnSO4 – speciﬁc metabolites in
plasma were phospholipid biosynthesis, glutathione metabolism, and
TCA cycle (Figure S9a); while in liver were the pentose phosphate
pathway, bile acid biosynthesis and the mitochondrial electron trans-
port chain (Figure S9b).
4. Discussion
4.1. Persistence of ZnO NPs in liver suggests possible particle-speciﬁc eﬀects
Key ﬁndings of this study are summarized in Table 1. Both ZnO NPs
and ZnSO4 induced acute physiological responses, including elevated
levels of hepatic toxicity biomarker, increased antioxidant activities
and proinﬂammatory responses following the initial exposure. Con-
tribution of ZnO dissolution to the ZnO NP-induced eﬀects was sub-
stantiated by the overlapping metabolites shared by ZnO NP and ZnSO4
(Fig. 4a and 4b). However, it is interesting that the signiﬁcant accu-
mulation of Zn in several major metabolizing organs was only found in
the ZnO NP treatment rather than the ZnSO4 treatment. In addition,
XAFS results suggest that 29% of the Zn accumulated in liver was still in
particulate form after 7 days of exposure, while in spleen, a much lower
percentage (2.3%) of accumulated Zn was in particulate form (Fig. 1).
This provide a direct evidence for the longer persistence of particle in
liver and possibility of nano-speciﬁc hepatic toxicity.
The dissolution of ZnO NPs in diﬀerent biological matrices was
studied (Fig. 6) to shed additional light on the observed metabolic re-
sponses. Only 0.44% and 0.28% of Zn2+ dissolved from ZnO NPs in
water and 0.1% SCMC saline solution (Fig. 6a), respectively, after 48 h
incubation. Signiﬁcantly enhanced dissolution (21.3%) was observed in
artiﬁcial lysosome ﬂuid (ALF) solution which is acidic (Fig. 6a). To
simulate more realistic scenarios, the dissolution of ZnO NPs was also
measured in rat serum and liver S9 extract pooled from homogenized
liver of rat. The percentage of free Zn2+ released in serum reached the
maximum (37%) after 1 h incubation and decreased with increasing
incubation time and remained constant after 4 days of incubation
(Fig. 6b). The decrease may be due to the binding of Zn2+ with phos-
phates that were abundant in serum (Bansal, 1990). The amount of free
Zn2+ dissolved from ZnO NPs in liver S9 increased over time and
reached 56% on day 2 and remained constant until day 5 when it
started decreasing (Fig. 6c). Transmission electron microscope (TEM)
images (Fig. 6d-f) showed that ZnO NPs lost their original morphology
after incubation in serum and liver S9 extract, although there were still
some particles after 7 days of incubation. All the results suggest that
ZnO NPs can be readily dissolved under various biological conditions,
however, ZnO NPs cannot fully dissolve in short periods (7 days in this
study), suggesting that long term eﬀects induced by the persistence of
particulate ZnO are possible. Longer-term studies are warranted by
these results.
4.2. Activation of anti-oxidative mechanism to mitigate ZnO NP-induced
oxidative stress
A distinct class of antioxidant-related metabolites were aﬀected by
exposure to ZnO NPs but not by ZnSO4 in both plasma (Fig. 7a) and
liver (Fig. 7b). Firstly, the GSH biosynthesis process was largely af-
fected. The levels of GSH precursors (glycine and glutamate) and the
intermediates in glycine metabolism (creatine, betaine and cystine in
plasma, glyceric acid, serine, and threonine in liver tissue) were all
Fig. 3. Eﬀects of ZnO NPs and ZnSO4 on the release of inﬂammatory cytokines in plasma (a), GSH and MDA levels, CAT and SOD activities, and ROS change in rat
plasma (b) and liver (c) after intranasal exposure. Values of CAT, SOD and MDA were normalized by the total protein content in each sample. Data is expressed as
mean ± SD (n = 10). CT indicates control group without Zn treatment. *p < 0.05, ** p < 0.01 indicate signiﬁcant diﬀerence compared with CT.
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elevated in the ZnO NP group. Pyroglutamic acid, an intermediate in
GSH metabolism (Palmer 2010), was also increased in the liver
samples. In addition, other GSH- related metabolites, including cysteine
sulﬁnic acid and nicotinamide adenine dinucleotide phosphate (NADP),
were all increased in the ZnO NP- exposed group. In addition to GSH,
tryptophan (Moosmann and Behl, 2000), phenylalanine (Dong et al.,
2014), alanine (Grosser et al., 2004), and taurine (Gürer et al., 2001),
which are also critical components involved in antioxidative defense,
were all upregulated by ZnO NPs (Fig. 7). Higher production of gulo-
nolactone, which is essential substrate for biosynthesis of antioxidant
ascorbic acid, was also upregulated.
The high level of antioxidants detected indicated that the animals
were defending themselves against the ZnO NP - induced oxidative
stress. Indeed, methionine sulfoxide, an oxidative stress biomarker, was
increased in ZnO NP group (Fig. 7a). GSH: GSSG ratio, another oxida-
tive stress biomarker, was also decreased in that hepatic GSSG level was
signiﬁcantly elevated (Fig. 7b) while GSH did not show signiﬁcant al-
teration based on both biochemical and metabolic data (Fig. 3c and
Figure S8).
Compared to ZnO NPs, ZnSO4 induced much less changes in anti-
oxidant metabolism (Fig. 4). Only 7 antioxidant-related metabolites
were altered by ZnSO4 in plasma (with 5 being common with ZnO NPs)
and 4 in liver (all of which overlapped with the metabolites aﬀected by
ZnO NPs). Taken together, the data convincingly demonstrated that
ZnO NPs caused oxidative stress in liver, and a distinct class of anti-
oxidant pathways were activated to defend against the oxidative in-
juries arising from the ZnO NPs compared to those induced in response
to the ZnSO4.
4.3. ZnO NP-induced oxidative stress alters cellular bioenergetics
Reports have shown that stress responses such as antioxidative ac-
tivity may impact the energy balance (Rabasa and Dickson, 2016).
Using the targeted metabolomic approach, we found that ATP levels
were exclusively elevated by 24% in the ZnO NP treatment (Fig. 8a),
suggesting a high demand for energy to compensate for the NP – in-
duced stress. However, for the ZnSO4 group, ATP production was not
aﬀected.
Fig. 4. Venn diagrams showing the number of perturbed metabolites in plasma
(a) and liver (b).▲ and ▾ indicate the metabolites were up- or down-regulated,
respectively. Metabolites that had VIP > 1 and p < 0.05 are deﬁned as sig-
niﬁcantly changed metabolites. (c) and (d) show the number of signiﬁcantly
aﬀected metabolites involved in diﬀerent biological metabolism pathways in
plasma and liver, respectively, after exposure to ZnO NPs and ZnSO4.
Fig. 5. Metabolite set enrichment analysis of ZnO NP -speciﬁc metabolites in plasma (a) and liver (b) 7 days after the single intranasal exposures.
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We also found that mitochondrial metabolism, and more particu-
larly the TCA cycle, a mainstream of ATP production, was interrupted.
For example, in the liver, succinate, an intermediate in the TCA cycle,
was speciﬁcally elevated in ZnO NP exposed group (Figure S8b). Glu-
tamate, which can contribute to the α-ketoglutarate pool and fuel the
TCA cycle, was elevated in ZnO NPs group (Figure S8b). Targeted
metabolomics analysis revealed that the levels of hepatic energetic
metabolites involved in the TCA cycle were upregulated by ZnO NPs
(Fig. 8a). In particular, succinate and oxaloacetate were elevated by
48% and 17%, respectively. The increased levels of TCA cycle-related
metabolites could potentially preserve liver bioenergetics to cope with
stress when energy is in high demand. Metabolites that participate in
oxidative phosphorylation (ATP formation), such as ﬂavin adenine di-
nucleotide (FAD) and NADP(H), were also exclusively elevated in the
ZnO NP group. Nicotinic acid, the precursor of NADP, was signiﬁcantly
reduced by 20%, indicating a high conversion rate to NADP (Fig. 8a).
Increased oxidative phosphorylation activity may allow more genera-
tion of ATP molecules and thus contributes to the continuous supply of
liver bioenergy. These observations therefore raise the possibility of
enhancement of mitochondrial metabolism when ZnO NPs were accu-
mulated in the liver, possibly to defend against the NP-induced oxida-
tive stress. In contrast, in the ZnSO4-exposed group, TCA cycle sub-
strates such as aconitate and malic acid, were signiﬁcantly decreased in
the plasma (Figure S8a), and targeted metabolomic analysis showed
fumarate was markedly decreased by 18% in the liver (Fig. 8a), in-
dicating Zn2+ ions have a diﬀerent mode of action on energy meta-
bolism compared to ZnO NPs. Mitochondrial alterations as a con-
sequence of NP exposure was also reported in a few previous studies,
including decreased activity of the three proton pumping complexes
(Xue et al., 2014), disturbance of concentrations of intermediates in the
TCA cycle and decrease in capacity for ATP synthesis (Shim et al.,
2012).
Interestingly, glycolytic metabolites, including acetylglucosamine 1-
phosphate (Figure S8b), phosphoenolpyruvate (PEP), dihydroxyacetone
phosphate (DHAP), and glycerol 3-phosphate (Gro3P) (Fig. 8b) were
signiﬁcantly increased by 57%, 43%, 34%, and 17%, respectively,
while pyruvate was decreased in the ZnO NP group (Fig. 8b). The re-
duced levels of pyruvate may stem from the increased ﬂux of pyruvate
to TCA cycle. Thiamine pyrophosphate (TPP) is a cofactor that favors
conversion of ribose-5-phosphate into the glycolytic intermediates such
as fructose-6-phosphate and glyceraldehyde-3-phosphate. Targeted
analysis showed that TPP level signiﬁcantly elevated (27%) in the ZnO
NP group (Fig. 8b), indicating an increased ﬂux towards the glycolytic
pathway. Although ATP production through glycolytic process is not as
eﬃcient as the TCA cycle, the yield rate is much faster than that of
oxidative phosphorylation. The increased glycolytic substrate reserves
Table 1
Summary of the key diﬀerences between ZnO NP or ZnSO4 exposure, conﬁrming that ZnO NPs have a very diﬀerent mode of action compared to Zn2+ ions, and that a
sizable % of the particles remain intact over suﬃcient durations (7 days) to induce distinct alterations to the liver function.
ZnO NPs ZnSO4
Zn Accumulation Liver, Kidney, Spleen, Testis No accumulation
Zinc Form in Liver 29% ZnO NPs, 71% Zn-complexes 100% Zn-complexes
Zinc Form in Spleen 2.3% ZnO NPs, 97.7% Zn-complexes 100% Zn-complexes
Organ Weight Increase in thymus Decrease in weights of heart and lung
Relative Organ Weight Decrease in heart Decrease in brain and heart
Blood Biochemistry No change Decrease in amylase; increase in glucose
Liver Function Indicators No change Increase in ALP
Oxidative Stress Markers in Liver Increase in CAT, SOD, MDA, ROS Increase in CAT, SOD, MDA, ROS
Pro-inﬂammatory Cytokines in plasma Increase in IL-1α, IL-1β, IL-10, and TNFα; Increase in IL-1β, IL-6, IL-10, and TNFα
Perturbed number of metabolites 55 in plasma; 75 in liver 56 in plasma; 37 in liver
Perturbed pathways or biofunctions Enhanced energy metabolism
Enhanced antioxidant response
Increased metabolites in nucleotide metabolism
Disrupted cell membrane homeostasis
Neuromodulation
DNA damage
Depressed energy metabolism
Enhanced antioxidant response
Decreased metabolites in nucleotide metabolism
Disrupted cell membrane homeostasis
Fig. 6. Percentage of free Zn2+ dissolved from ZnO NPs in ddH2O, 0.1% SCMC and ALF (pH 4.5) (a), rat serum (b) and liver S9 extract (c). TEM images of ZnO NPs
incubated with serum for 3 h (d and e) and with liver S9 extract for 7 days (f). Image e is the magniﬁcation of the rectangle area highlighted in d.
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may serve as a compensatory energy reservoir when cells are in urgent
demand of bioenergy. Moreover, increased glycolytic ﬂux may ensure a
rich supply of substrates that can be redirected into energy-consuming
anabolic pathways. In the ZnSO4 group, no signiﬁcant changes in gly-
colytic metabolites were identiﬁed (Fig. 8b), providing more evidence
that ZnO NPs and ZnSO4 ions have diﬀerent mode of action.
In addition to carbohydrates, other major energy sources such as
amino acids and fatty acids were exclusively elevated after ZnO NP
exposure (Figure S8b), suggesting greater protein breakdown, the end
substrate of which can then contribute to energy production. While in
ZnSO4 group, we found levels of all amino acids and most of dipeptides,
were all decreased in the plasma, demonstrating that protein break-
down was inhibited in the ZnSO4-exposed group (Figure S8a). Plasma
glycerol levels increased in ZnO NP group (Figure S8a), indicating ac-
celerated lipolysis (Herrera and Amusquivar, 2000). Targeted metabo-
lomic analysis revealed levels of 13 fatty acids in plasma and 3 in liver
were found to be speciﬁcally reduced in ZnO NP group (Figure S10a),
which may arise from the accelerated oxidation of fatty acid. In the
ZnSO4 treatment, 1 and 8 fatty acids (Figure S10b) were particularly
decreased in plasma and liver. There were also some overlapping fatty
acids (7 in liver) that were depressed by both ZnO NPs and ZnSO4
(Figure S10c). Taken together, these indicate ZnO NPs have a diﬀerent
mode of action on fatty acid metabolism compared to Zn2+ ions in
addition to the common eﬀect that arises from the ions released from
the ZnO NPs. Enhanced reserves of glycolytic and TCA cycle substrates,
and amino acids may be a metabolic strategy to supply the excess de-
mand for ATP required to defend against the stress induced by ZnO NPs.
However, these processes can only alleviate the negative impacts of
oxidative stress for a limited period. The irreversible impact of cell
injury and subsequent cell death may occur if the ZnO NPs remain in
the liver over extended periods, or where repeated exposures occur, an
area which needs more investigation in the future.
4.4. Other ZnO NP – interrupted biological pathways
Additional biological pathways were also perturbed by the exposure
to ZnO NPs as compared to the ZnSO4 treatment. A dramatic increase in
metabolites that are related to purine and pyrimidine synthesis in re-
sponse to the ZnO NP exposure was observed. For example, the levels of
2-thiocytidine, thymine, 3-methyluridine were signiﬁcantly elevated by
296%, 40%, and 21%, respectively (Figure S11a). There was also an
increase in pentose phosphate pathway intermediates, such as 2-deox-
yribose 5-phosphate, ribose, and ribulose 5-phosphate (Figure S8),
which are important for nucleotide synthesis. Increase in these inter-
mediates may explain the higher level of nucleosides and nucleotides
observed in the ZnO NP-exposed group relative to the control and
ZnSO4 treatment. Moreover, ZnO NPs induced elevated DNA degrada-
tion, evidenced by increased deoxycytidine monophosphate and deox-
yadenosine monophosphate (Figure S8), which are monomers that
make up DNA. By contrast, in the ZnSO4 group, levels of purines and
pyrimidines, including 2′-O-methyladenosine, adenine, purine, guano-
sine, adenosine, 1-methylxanthine, xanthosine, deoxycytidine, and cy-
tidine, were signiﬁcantly decreased (Figure S11b).
The intermediates related to biosynthesis of key cell membrane
components, such as phosphoethanolamine and phosphorylcholine,
were notably elevated in liver of ZnO NP exposed group but not the
ZnSO4 group (Figure S8). In contrast, phosphorylcholine, glyceropho-
sphocholine and LPA (18:1(9Z)/0:0) were all decreased in plasma in
ZnSO4 group (Figure S8). In addition, depression of α-linolenic acid, a
structural component of cell membrane, and an intermediate in its
metabolism, arachidonic acid, was exceptionally induced by ZnO NP,
but not by ZnSO4 (Figure S10a). These further proved that ZnO NP has
diﬀerent mode of action compared to Zn2+ ions, and the accumulation
of ZnO NPs may speciﬁcally disrupt cell membrane homeostasis.
Despite the extensive reports of ZnO NPs neurotoxicity (Elshama
et al., 2017; Valdiglesias et al., 2013), there is still no convincing evi-
dence of the particle – originated eﬀect in the literature. We found
several neuro-related metabolites, such as N-acetylaspartylglutamate,
Fig. 7. Relative levels of antioxidant - related metabolites in plasma (a) and liver (b) after ZnO NP and ZnSO4 exposure. Rows indicate metabolites. The degree of
change in metabolite concentration following ZnO NP or ZnSO4 exposure is color - coded. * indicates signiﬁcant diﬀerence when compared with control.
Z. Guo, et al. Environment International 136 (2020) 105437
9
aminoadipic acid, glutamate, phenylalanine, valine and creatine, were
exclusively up-regulated by the ZnO NP treatment but not in ZnSO4
group (Figure S8 and Figure S12), suggesting particle-speciﬁc eﬀects of
ZnO NPs to the nervous system. Thus, apart from the eﬀects on anti-
oxidative activity and energy metabolism discussed above, the observed
metabolic perturbations could also be reﬂective of other aspects of ZnO
NP toxicity, related speciﬁcally to the particulate form, which may
require further investigation.
In conclusion, persistence of ZnO NPs in liver and speciﬁc eﬀects on
metabolic proﬁle induced by ZnO NPs provide direct evidences of
particle-speciﬁc eﬀects of ZnO NPs that cannot be associated solely with
the dissolution of the ZnO NPs, as this should induce more classical
Zn2+ ion toxicity pathways, which were observed to only a very limited
eﬀect since just under 18% of the up-/down-regulated metabolites
observed in the liver following ZnO NP exposure were common to the
Zn2+ ion exposure. NPs - induced oxidative stress, which in turn en-
hanced the cellular bioenergetics by promoting glycolysis, TCA cycle,
oxidative phosphorylation, and protein and fat breakdown, was the
main mode of action for the ZnO NPs, while ZnSO4, beyond the anti-
oxidant response, decreased energy metabolism by suppressing the TCA
cycle and protein breakdown, which are distinct modes of action
compared to those induced by ZnO NPs. Further studies are required to
explore in more detail the mechanisms of the nano-speciﬁc eﬀects, and
the consequences over the longer term and from multiple exposures to
NPs, which can persist in the liver over extended periods even for
highly soluble NPs such as ZnO NPs.
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